1. Sertznig P, von Felbert V, Megahed M. Porokeratosis: present concepts. J Eur Acad Dermatol Venereol. 2012; 26:404–412.
Article
2. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015; 15:397–408.
Article
3. Mowla SN, Lam EW, Jat PS. Cellular senescence and aging: the role of B-MYB. Aging Cell. 2014; 13:773–779.
Article
4. Scola N, Skrygan M, Wieland U, Kreuter A, Gambichler T. Altered gene expression in squamous cell carcinoma arising from congenital unilateral linear porokeratosis. Clin Exp Dermatol. 2012; 37:781–785.
Article
5. Tsujita J, Kaku Y, Ichiki T, Eto A, Maemura H, Otsuka A, et al. Immunohistological expression of p16INK4a is commonly present both in benign and malignant sweat gland neoplasias. Fukuoka Igaku Zasshi. 2015; 106:323–329.
6. Arranz-Salas I, Sanz-Trelles A, Ojeda DB. p53 alterations in porokeratosis. J Cutan Pathol. 2003; 30:455–458.
Article
7. Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J Cutan Pathol. 2004; 31:544–549.
Article
8. Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB. p16 immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases. Int J Gynecol Pathol. 2016; 35:385–393.
Article
9. Tschandl P, Berghoff AS, Preusser M, Pammer J, Pehamberger H, Kittler H. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo. Br J Dermatol. 2016; 174:364–370.
Article
10. Zhang C, Toulev A, Kamarashev J, Qin JZ, Dummer R, Döbbeling U. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol. 2007; 38:995–1002.
Article